Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

867178

registered interest
date	19/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will bring forward the scheduled review of the Cystic Fibrosis drug Orkambi.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	133296
answer	answer is ministerial correction date of answer 27/03/2018 answer text <p>The Government has made no such assessment itself. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources. NICE published guidance on the use of Orkambi for the treatment of cystic fibrosis in July 2016 and was not able to recommend it for routine use on the NHS.</p><p> </p><p>NICE has advised that it has not been notified of any new data published in February 2018 related to the use of Orkambi. NICE periodically reviews its technology appraisal guidance to determine whether any new evidence, including new trial data, has emerged that may affect its original recommendations. NICE is next scheduled to review its guidance on the use of Orkambi in July 2019, at which point it will conduct a search for new evidence. NICE’s guidance may be reviewed before the expected review date if significant new evidence emerges that is likely to change the recommendations. The company or any other stakeholder can alert NICE to new evidence in line with its established processes to request an early review.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 133299 question first answered 27/03/2018 11:54:59 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

867181

registered interest
date	19/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made for the implications for its policy of new data published by Vertex Pharmaceuticals in February 2018 on the Cystic Fibrosis drug Orkambi.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	133299
answer	answer is ministerial correction date of answer 27/03/2018 answer text <p>The Government has made no such assessment itself. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources. NICE published guidance on the use of Orkambi for the treatment of cystic fibrosis in July 2016 and was not able to recommend it for routine use on the NHS.</p><p> </p><p>NICE has advised that it has not been notified of any new data published in February 2018 related to the use of Orkambi. NICE periodically reviews its technology appraisal guidance to determine whether any new evidence, including new trial data, has emerged that may affect its original recommendations. NICE is next scheduled to review its guidance on the use of Orkambi in July 2019, at which point it will conduct a search for new evidence. NICE’s guidance may be reviewed before the expected review date if significant new evidence emerges that is likely to change the recommendations. The company or any other stakeholder can alert NICE to new evidence in line with its established processes to request an early review.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 133296 question first answered 27/03/2018 11:54:59 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

867182

registered interest
date	19/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent discussions has his Department had with Cystic Fibrosis sufferers on the provision of the drug Orkambi by the NHS.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	133300
answer	answer is ministerial correction date of answer 27/03/2018 answer text <p>The Government met with the Cystic Fibrosis Trust, which represents patients with cystic fibrosis, in March 2017 to discuss access to the drug Orkambi. The Government has also had regular correspondence with patients with cystic fibrosis concerning the availability of Orkambi. We are also aware that NHS England has been in regular contact with the Cystic Fibrosis Trust about this matter.</p><p> </p><p>The Government welcomes the ongoing discussions between NHS England and the manufacturer of Orkambi, Vertex, to seek to agree a deal that would make Orkambi available to National Health Service patients in a way that represents value to the taxpayer.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 27/03/2018 11:56:18 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

850730

registered interest
date	27/02/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dental Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve access to NHS dental care in (a) York, (b) North Yorkshire and (c) England.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	129970
answer	answer is ministerial correction date of answer 07/03/2018 answer text <p>NHS England has a legal duty to commission National Health Service dental services to meet the needs of the local population. NHS England also has arrangements in place to help patients who cannot find a local dentist that is accepting new patients.</p><p> </p><p>Access nationally remains high with 22.1 million adults having seen an NHS dentist in the last 24 months ending in 31 December 2017 and 6.9 million children having seen an NHS dentist in the last 12 months. However, there are areas where there is further to go to ensure that all those who want to access NHS dental care can do so.</p><p> </p><p>NHS England (Yorkshire and the Humber) is currently reviewing how it can improve access to NHS dentists from April 2018, prioritising areas where access is particularly difficult.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 07/03/2018 16:53:33 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

850731

registered interest
date	27/02/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dental Services: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure all children have access to NHS dental services.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	129971
answer	answer is ministerial correction date of answer 07/03/2018 answer text <p>NHS England has a legal duty to commission National Health Service dental services to meet the needs of the local population. NHS England also has arrangements in place to help patients who cannot find a local dentist that is accepting new patients.</p><p> </p><p>The proportion of children seeing a dentist at least once a year is already high with 6.8 million children having seen a dentist in the 12 months ending 31 December 2017. This is 110,767 more children than saw a dentist in the 12 month period ending 31 December 2016.</p><p> </p><p>Survey data suggests 75% of children are now decay free at five years old. But there is further to go to ensure all children benefit from this improvement. The proposed new contract being tested includes a clinical pathway which supports dentists to provide the most appropriate preventative care as well as active treatment. Alongside this NHS England is targeting children in areas of particularly high need.</p><p> </p><p>The ‘Starting Well’ programme has been launched in 13 high needs areas and aims to reach children not currently being seen regularly by a dentist. Starting Well core, a complementary programme NHS England is developing, will take the principles of approach and make it available as a broader model to any commissioner based on local assessment of need and priorities. This is expected to be available later in 2018.</p><p><strong> </strong></p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 07/03/2018 10:31:58 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

832935

registered interest
date	29/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cervical Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the take-up rate for cervical screening in (a) York and (b) England.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	125251
answer	answer is ministerial correction date of answer 06/02/2018 answer text <p>The North Yorkshire and York Health Improvement Plan includes halting the decline in cervical screening coverage by delivering additional training to general practice staff; working with the clinical commissioning group engagement agents and plans to enlist volunteer cancer champions to attend community events and work with local businesses to promote cervical screening.</p><p> </p><p>Public Health England (PHE), the Department and NHS England continue to work together to understand and redress the falling participation in the National Health Service cervical screening programme. A range of work is being undertaken by PHE to understand the reasons for the decline in uptake and to support the NHS and local authorities (LAs) to address them. They include access to timely and useful data for benchmarking, evidence on best practices to increase uptake among women who wish to be screened, using governance levers to advice NHS and LAs and working in partnership with commissioners, providers and charities.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 06/02/2018 12:06:53 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

823445

registered interest
date	16/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Influenza: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the availability of stocks of flu vaccines in (a) York and (b) England.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	122923
answer	answer is ministerial correction date of answer 24/01/2018 answer text <p>Flu vaccines for people aged 18 years and older are procured directly from manufacturers and suppliers by providers. The procurement and distribution of flu vaccines for the children’s aspect of the national flu programme is managed by Public Health England.</p><p> </p><p>Flu vaccine remains available to order from manufacturers and suppliers across England for both the adult and the children’s aspects of the national flu immunisation programme.</p><p> </p><p>Officials are continuously monitoring the flu vaccine supply landscape to enable timely and appropriate action to be taken in the event that demand begins to outweigh the amount of flu vaccine that is currently available to patients.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 122924 question first answered 24/01/2018 11:59:58 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

823446

registered interest
date	16/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Influenza: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to increase the supply of flu vaccines to areas in the event that there are shortfalls of such vaccines during Winter 2017-18.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	122924
answer	answer is ministerial correction date of answer 24/01/2018 answer text <p>Flu vaccines for people aged 18 years and older are procured directly from manufacturers and suppliers by providers. The procurement and distribution of flu vaccines for the children’s aspect of the national flu programme is managed by Public Health England.</p><p> </p><p>Flu vaccine remains available to order from manufacturers and suppliers across England for both the adult and the children’s aspects of the national flu immunisation programme.</p><p> </p><p>Officials are continuously monitoring the flu vaccine supply landscape to enable timely and appropriate action to be taken in the event that demand begins to outweigh the amount of flu vaccine that is currently available to patients.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 122923 question first answered 24/01/2018 11:59:58 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

819992

registered interest
date	10/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will introduce a national minor ailments scheme as part of the Pharmacy Integration Fund, and if he will make a statement.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	122064
answer	answer is ministerial correction date of answer 18/01/2018 answer text <p>Minor ailment services are commissioned locally by the National Health Service according to need. The purpose of the Pharmacy Integration Fund (PhIF) is to try out and evaluate new ways of integrating pharmacists and community pharmacy into the wider health care system. National commissioning of NHS pharmaceutical services is arranged through the Community Pharmacy Contractual Framework. In December 2017, under the PhIF, NHS England commenced a pilot urgent minor illness care pathway of direct referral from NHS 111 to community pharmacy. The outcome of this pilot will inform future commissioning decisions.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/01/2018 14:11:29 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

800571

registered interest
date	04/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neuromuscular Disorders
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the (a) extent and (b) effect on patient care of variation in specialist services for multiple sclerosis and Parkinson's among clinical commissioning groups in England.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	117192
answer	answer is ministerial correction date of answer 12/12/2017 answer text <p>We know that variation exists between clinical commissioning groups (CCGs) in the provision of care for neurological conditions, such as Parkinson’s disease and multiple sclerosis. Whilst it is right that CCGs have autonomy to shape services for local populations, there is a range of work ongoing at a national level to identify unwarranted variation in order to drive improvement, including:</p><p> </p><p>- Through the RightCare programme, which was rolled out to every CCG in 2016/17, NHS England provides practical support to commissioners to tackle unwarranted variation and identify improvements and savings, including for neurological services;</p><p>- Public Health England’s Neurology intelligence network collates and interprets data on adult neurological conditions to provide intelligence for the National Health Service, policy makers, and clinicians; and</p><p>- The Getting it Right First Time programme, supported by NHS Improvement, expanded earlier in 2017 to include neurology and will soon provide insight to demonstrate the value of better neurological services both in hospitals and in the community.</p><p> </p><p>NHS England will continue to work with the Neurological Alliance (an umbrella organisation for neurological condition charities) to support the new national Neurology Advisory Group (NAG), led by consultant neurologist Professor Adrian Williams. The NAG brings together system partners, professional bodies stakeholders to align work to improve neurological care, and has working to understand how best to utilise new and emerging data in services and outcomes. More information on national initiatives to reduce unwarranted variation and drive improvement can be found at the following links:</p><p> </p><p><a href="http://www.england.nhs.uk/rightcare/" target="_blank">www.england.nhs.uk/rightcare/</a></p><p> </p><p><a href="http://www.gov.uk/guidance/neurology-data-and-analysis-a-guide-for-health-professionals" target="_blank">www.gov.uk/guidance/neurology-data-and-analysis-a-guide-for-health-professionals</a></p><p> </p><p><a href="http://gettingitrightfirsttime.co.uk/" target="_blank">gettingitrightfirsttime.co.uk/</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 117193 question first answered 12/12/2017 17:07:27 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy